A Phase 1 Study of Alisertib (MLN8237) in Combination With mFOLFOX in Gastrointestinal Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Alisertib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Gastrointestinal cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 06 Jun 2017 Results (n=13) assessing the safety of alisertib + mFOLFOX combination in patients with gastrointestinal cancers, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 27 Apr 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Jun 2017.